

William V Bobo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5112063/publications.pdf>

Version: 2024-02-01

126
papers

4,093
citations

109264

35
h-index

149623

56
g-index

130
all docs

130
docs citations

130
times ranked

6116
citing authors

#	ARTICLE	IF	CITATIONS
1	Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth. <i>JAMA Psychiatry</i> , 2013, 70, 1067.	6.0	194
2	Prevalence of Multimorbidity in a Geographically Defined American Population. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1336-1349.	1.4	193
3	Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. <i>BMJ Open</i> , 2015, 5, e006413-e006413.	0.8	180
4	The PHQ-9 Item 9 based screening for suicide risk: a validation study of the Patient Health Questionnaire (PHQ)â9 Item 9 with the Columbia Suicide Severity Rating Scale (C-SSRS). <i>Journal of Affective Disorders</i> , 2018, 232, 34-40.	2.0	136
5	Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. <i>Menopause</i> , 2018, 25, 1069-1085.	0.8	122
6	Increasing pregnancy-related use of prescribed opioid analgesics. <i>Annals of Epidemiology</i> , 2013, 23, 498-503.	0.9	111
7	Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001â2007: a population-based study of 585,615 deliveries. <i>Archives of Women's Mental Health</i> , 2013, 16, 149-157.	1.2	107
8	Antidepressant discontinuation syndrome. <i>American Family Physician</i> , 2006, 74, 449-56.	0.1	100
9	Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. <i>Journal of Women's Health</i> , 2019, 28, 117-134.	1.5	96
10	KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. <i>Depression and Anxiety</i> , 2016, 33, 698-710.	2.0	94
11	Continuation phase intravenous ketamine in adults with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2016, 206, 300-304.	2.0	80
12	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <scp>CHOICE</scp>). <i>Bipolar Disorders</i> , 2015, 17, 212-223.	1.1	77
13	Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 151, 722-727.	2.0	76
14	PharmacogenomicsâDriven Prediction of Antidepressant Treatment Outcomes: A MachineâLearning Approach With MultiâTrial Replication. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 855-865.	2.3	69
15	Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness). <i>Journal of Clinical Psychiatry</i> , 2016, 77, 90-99.	1.1	69
16	Trends in the Use of Antiepileptic Drugs among Pregnant Women in the US, 2001â2007: A Medication Exposure in Pregnancy Risk Evaluation Program Study. <i>Paediatric and Perinatal Epidemiology</i> , 2012, 26, 578-588.	0.8	68
17	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 191, 216-221.	2.0	62
18	Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 114-127.	0.7	60

#	ARTICLE	IF	CITATIONS
19	Validation of the 17-item Hamilton Depression Rating Scale: definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. <i>Human Psychopharmacology</i> , 2016, 31, 185-192.	0.7	60
20	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. <i>Translational Psychiatry</i> , 2018, 8, 10.	2.4	59
21	Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. <i>JAMA Psychiatry</i> , 2020, 77, 1246.	6.0	58
22	The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1532-1551.	1.4	55
23	The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2015, 17, 528-535.	1.1	52
24	Concise Review for Physicians and Other Clinicians: Postpartum Depression. <i>Mayo Clinic Proceedings</i> , 2014, 89, 835-844.	1.4	51
25	Prevalence of Combined Somatic and Mental Health Multimorbidity: Patterns by Age, Sex, and Race/Ethnicity. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1483-1491.	1.7	48
26	Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 2007, 22, 249-267.	0.9	46
27	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. <i>Journal of Affective Disorders</i> , 2011, 133, 467-476.	2.0	45
28	Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 794-801.	0.9	44
29	Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. <i>Translational Psychiatry</i> , 2018, 8, 188.	2.4	44
30	Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2015, 172, 1251-1258.	4.0	43
31	Risperidone long-acting injectable (Risperdal Consta [®]) for maintenance treatment in patients with bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1637-1658.	1.4	41
32	A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1602-1610.	1.1	40
33	Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know. <i>CNS Spectrums</i> , 2006, 11, 14-24.	0.7	39
34	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65.	1.3	38
35	Sex differences in the risk of rapid cycling and other indicators of adverse illness course in patients with bipolar I and II disorder. <i>Bipolar Disorders</i> , 2015, 17, 670-676.	1.1	37
36	The relative influence of individual risk factors for attempted suicide in patients with bipolar I versus bipolar II disorder. <i>Journal of Affective Disorders</i> , 2018, 225, 489-494.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Association of Cytomegalovirus and <i>Toxoplasma gondii</i> Antibody Titers With Bipolar Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 1285.	6.0	36
38	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	2.0	36
39	Selective serotonin reuptake inhibitor treatment of post traumatic KlÃ¼ver-Bucy syndrome. <i>Brain Injury</i> , 1999, 13, 59-62.	0.6	35
40	Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. <i>IEEE Computational Intelligence Magazine</i> , 2018, 13, 20-31.	3.4	34
41	Characteristics of Repeat Users of an Inpatient Psychiatry Service at a Large Military Tertiary Care Hospital. <i>Military Medicine</i> , 2004, 169, 648-653.	0.4	32
42	The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2011, 130, 106-113.	1.1	32
43	Soldier Peer Mentoring Care and Support: Bringing Psychological Awareness to the Front. <i>Military Medicine</i> , 2005, 170, 355-361.	0.4	31
44	Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. <i>Journal of Psychopharmacology</i> , 2012, 26, 1201-1210.	2.0	29
45	Current landscape, unmet needs, and future directions for treatment of bipolar depression. <i>Journal of Affective Disorders</i> , 2014, 169, S17-S23.	2.0	29
46	Clinical features of bipolar spectrum with binge eating behaviour. <i>Journal of Affective Disorders</i> , 2016, 201, 95-98.	2.0	29
47	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , 2018, 238, 1-7.	2.0	28
48	Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a tennessee medicaid study. <i>BMC Medical Research Methodology</i> , 2011, 11, 157.	1.4	27
49	Quantifying the impact of chronic conditions on a diagnosis of major depressive disorder in adults: a cohort study using linked electronic medical records. <i>BMC Psychiatry</i> , 2016, 16, 114.	1.1	27
50	Long-term risk of myocardial infarction and stroke in bipolar I disorder: A population-based Cohort Study. <i>Journal of Affective Disorders</i> , 2016, 194, 120-127.	2.0	27
51	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	1.4	27
52	The Effect of Psychiatric Third-Year Rotation Setting on Academic Performance, Student Attitudes, and Specialty Choice. <i>Academic Psychiatry</i> , 2009, 33, 105-111.	0.4	26
53	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	2.0	26
54	A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2010, 177, 286-293.	1.7	24

#	ARTICLE	IF	CITATIONS
55	Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 61-91.	1.3	22
56	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. <i>Journal of Affective Disorders</i> , 2016, 192, 212-218.	2.0	22
57	Time trends of antidepressant drug prescriptions in men versus women in a geographically defined US population. <i>Archives of Women's Mental Health</i> , 2014, 17, 485-492.	1.2	21
58	Psychotherapy use in bipolar disorder: Association with functioning and illness severity. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 453-461.	1.3	21
59	Evidence for a <i>SULT4A1</i> haplotype correlating with baseline psychopathology and atypical antipsychotic response. <i>Pharmacogenomics</i> , 2011, 12, 471-480.	0.6	20
60	Comparative Effectiveness of Second-Generation Antipsychotic Medications in Early-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 845-853.	2.3	20
61	Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges. <i>Drug, Healthcare and Patient Safety</i> , 2015, 7, 7.	1.0	20
62	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. <i>Translational Psychiatry</i> , 2021, 11, 513.	2.4	20
63	Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 109.	1.0	19
64	Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1193.	0.9	19
65	Clinical correlates of acute bipolar depressive episode with psychosis. <i>Journal of Affective Disorders</i> , 2017, 217, 29-33.	2.0	19
66	Efficacy, safety and tolerability of Symbyax [®] for acute-phase management of treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 651-670.	1.4	18
67	Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study. <i>BMC Medical Research Methodology</i> , 2012, 12, 128.	1.4	18
68	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	2.0	18
69	Complexity of Illness and Adjunctive Benzodiazepine Use in Outpatients With Bipolar I or II Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 68-74.	0.7	18
70	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 223, 146-152.	2.0	18
71	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. <i>Journal of Affective Disorders</i> , 2018, 225, 563-568.	2.0	18
72	Implementing the US Department of Health and Human Services definition of multimorbidity: a comparison between billing codes and medical record review in a population-based sample of persons 40-84 years old. <i>BMJ Open</i> , 2021, 11, e042870.	0.8	18

#	ARTICLE	IF	CITATIONS
73	A Randomized Open Comparison of Long-Acting Injectable Risperidone and Treatment as Usual for Prevention of Relapse, Rehospitalization, and Urgent Care Referral in Community-Treated Patients With Rapid Cycling Bipolar Disorder. <i>Clinical Neuropharmacology</i> , 2011, 34, 224-233.	0.2	17
74	The association of exercise during pregnancy with trimester-specific and postpartum quality of life and depressive symptoms in a cohort of healthy pregnant women. <i>Archives of Women's Mental Health</i> , 2017, 21, 215-224.	1.2	17
75	Recurring Episodes of Bellâ€™s Mania After Cerebrovascular Accident. <i>Psychosomatics</i> , 2009, 50, 285-288.	2.5	16
76	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. <i>Journal of Affective Disorders</i> , 2019, 246, 62-68.	2.0	16
77	The Management of Post Traumatic Stress Disorder (PTSD) in the Primary Care Setting. <i>Southern Medical Journal</i> , 2007, 100, 797-802.	0.3	16
78	Current Perspectives on Chief Residents in Psychiatry. <i>Academic Psychiatry</i> , 2007, 31, 270-276.	0.4	15
79	Multimorbidity, ageing and mortality: normative data and cohort study in an American population. <i>BMJ Open</i> , 2021, 11, e042633.	0.8	15
80	Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 369.	1.0	14
81	Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 27-37.	0.5	14
82	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. <i>Neuropsychopharmacology</i> , 2021, 46, 1272-1282.	2.8	14
83	Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8â€™week open label trial. <i>Human Psychopharmacology</i> , 2010, 25, 30-36.	0.7	13
84	The effect of regulatory advisories on maternal antidepressant prescribing, 1995â€™2007: an interrupted time series study of 228,876 pregnancies. <i>Archives of Women's Mental Health</i> , 2014, 17, 17-26.	1.2	13
85	Predictors of Return Visits Among Insured Emergency Department Mental Health and Substance Abuse Patients, 2005-2013. <i>Western Journal of Emergency Medicine</i> , 2017, 18, 884-893.	0.6	13
86	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	2.0	13
87	Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00461.	1.1	13
88	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2020, 266, 772-781.	2.0	13
89	Ketamine as a Preferred Substance of Abuse. <i>American Journal on Addictions</i> , 2002, 11, 332-334.	1.3	12
90	Association between history of psychosis and cardiovascular disease in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 518-527.	1.1	12

#	ARTICLE	IF	CITATIONS
91	Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. <i>Frontiers in Pharmacology</i> , 2019, 10, 83.	1.6	12
92	Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011. <i>Schizophrenia Research</i> , 2020, 215, 81-88.	1.1	12
93	The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	12
94	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. <i>Journal of Affective Disorders</i> , 2019, 246, 126-131.	2.0	11
95	Sex-specific effects of gain-of-function P2RX7 variation on bipolar disorder. <i>Journal of Affective Disorders</i> , 2019, 245, 597-601.	2.0	11
96	The Neurobiology of Schizophrenia. , 0, , 301-316.		11
97	Bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq1 1 0.784314 rgBT /Overl	2.0	10
98	Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. <i>Psychiatry Research</i> , 2010, 176, 114-119.	1.7	9
99	An electronic health record driven algorithm to identify incident antidepressant medication users. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 785-791.	2.2	9
100	Treatment outcomes of acute bipolar depressive episode with psychosis. <i>Depression and Anxiety</i> , 2018, 35, 402-410.	2.0	9
101	Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments?. <i>Pharmacogenomics</i> , 2019, 20, 983-988.	0.6	9
102	Mental health conditions diagnosed before bilateral oophorectomy: a population-based case-control study. <i>Menopause</i> , 2019, 26, 1395-1404.	0.8	9
103	Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 449-455.	1.1	9
104	Bi-directional association between depression and HF: An electronic health records-based cohort study. <i>Journal of Comorbidity</i> , 2020, 10, 2235042X2098405.	3.9	8
105	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2016, 205, 159-164.	2.0	7
106	Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods. , 2017, , .		7
107	Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression. <i>Annals of Clinical Psychiatry</i> , 2011, 23, 193-201.	0.6	7
108	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 412.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Melperone, an atypical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. <i>Human Psychopharmacology</i> , 2009, 24, 415-422.	0.7	6
110	Depressive Symptoms and Access to Mental Health Care in Women Screened for Postpartum Depression Who Lose Health Insurance Coverage After Delivery: Findings From the Translating Research Into Practice for Postpartum Depression (TRIPPD) Effectiveness Study. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1220-1228.	1.4	6
111	Post-traumatic stress disorder, anxiety, and depression among adults with congenital heart defects. <i>Birth Defects Research</i> , 2022, 114, 124-135.	0.8	6
112	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 21, 350-360.	1.1	5
113	Effects of a multidisciplinary quality of life intervention on sleep quality in patients with advanced cancer receiving radiation therapy. <i>Palliative and Supportive Care</i> , 2020, 18, 307-313.	0.6	5
114	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. <i>Journal of Psychiatric Research</i> , 2021, 140, 205-213.	1.5	5
115	Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 181-192.	0.4	4
116	A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2016, 55, 971-976.	1.6	3
117	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 994-1002.	1.3	3
118	Venlafaxine prescription claims among insured women of reproductive age and pregnant women, 2011-2016. <i>Birth Defects Research</i> , 2021, 113, 1052-1056.	0.8	2
119	Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 1347-1358.	3.1	2
120	Acute Bipolar Depression: A Review of the Use of Olanzapine/Fluoxetine. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S1945.	0.4	1
121	Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. <i>CNS Spectrums</i> , 2022, 27, 232-232.	0.7	1
122	A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 278-287.	0.7	1
123	More evidence of an association between antipsychotic drugs and the risk of diabetes in children and adolescents: a population-based study. <i>Evidence-Based Mental Health</i> , 2015, 18, e1-e1.	2.2	0
124	Relative Age Effect on Problematic Alcohol Use in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, , .	0.7	0
125	Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. <i>Psychopharmacology Bulletin</i> , 2021, 51, 109-124.	0.0	0
126	Positive Urine Drug Screens and External Mortality in Teenagers Who Present for Medical Care. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	1.1	0